论文部分内容阅读
[目的]探讨调强放疗同步化疗治疗晚期非小细胞肺癌的疗效。[方法]180例晚期非小细胞肺癌患者,随机分成对照组和治疗组,每组90例,两组都给予同步放化疗,化疗方案均为多西他赛单药化疗,对照组采用三维适行放疗,治疗组采用调强放疗,治疗周期为8周。[结果 ]治疗组与对照组的靶区平均剂量分别为(65.32±4.12)Gy和(62.34±5.13)Gy;靶区最高剂量分别为(69.42±5.31)Gy和(66.33±4.09)Gy,治疗组的靶区平均剂量和最高剂量均比对照组高(P<0.05)。对照组和治疗组治疗有效率分别为66.7%、83.3%,治疗组明显高于对照组(P<0.05)。治疗组的皮肤反应、消化道反应、血液毒性等不良反应发生情况明显少于对照组(P<0.05)。随访结果显示,治疗组的总生存时间、无疾病进展生存时间和1年生存率都明显高于对照组(P<0.05)。[结论]相对于三维适行放疗,调强放疗同步化疗方案治疗晚期非小细胞肺癌能获得更为理想的靶区剂量,能促进治疗疗效的提高,减少不良反应的发生,从而延长患者的生存时间。
[Objective] To investigate the effect of intensity modulated radiotherapy and concurrent chemotherapy in the treatment of advanced non-small cell lung cancer. [Method] One hundred and eighty patients with advanced non-small cell lung cancer were randomly divided into control group and treatment group, 90 cases in each group. Both groups were given concurrent chemoradiotherapy. The chemotherapy regimen was docetaxel single-agent chemotherapy. Radiotherapy, the treatment group with intensity-modulated radiotherapy, the treatment cycle was 8 weeks. [Results] The average dose of the target area in the treatment group and the control group were (65.32 ± 4.12) Gy and (62.34 ± 5.13) Gy, respectively. The highest dose of the target area was (69.42 ± 5.31) Gy and (66.33 ± 4.09) Gy, respectively The target group average dose and the highest dose were higher than the control group (P <0.05). The effective rates of the control group and the treatment group were 66.7% and 83.3% respectively, which were significantly higher in the treatment group than in the control group (P <0.05). Skin reaction, digestive tract reaction, hematotoxicity and other adverse reactions in the treatment group were significantly less than those in the control group (P <0.05). The follow-up results showed that the total survival time, disease-free survival time and 1-year survival rate were significantly higher in the treatment group than in the control group (P <0.05). [Conclusion] Compared with three-dimensional proper radiotherapy, IMRT regimen can achieve more ideal target dose for advanced non-small cell lung cancer, which can promote the therapeutic efficacy and reduce the incidence of adverse reactions, thereby prolonging the survival of patients time.